openPR Logo
Press release

GLP-1 Analogues Market worth $471.1 billion by 2032 | MarketsandMarkets Trademark

10-09-2024 06:38 PM CET | Health & Medicine

Press release from: ABNewswire

North America, particularly the US, is expected to exhibit the highest growth rate in the GLP-1 Analogue market during the forecast period. This projection stems from increasing adoption of GLP-1 drugs for diabetes and obesity treatment, supported by well

North America, particularly the US, is expected to exhibit the highest growth rate in the GLP-1 Analogue market during the forecast period. This projection stems from increasing adoption of GLP-1 drugs for diabetes and obesity treatment, supported by well

Browse 405 market data Tables and 59 Figures spread through 315 Pages and in-depth TOC on "GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032
The global GLP-1 analogues market [https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] is poised for substantial growth, projected to expand from USD 47.4 billion in 2024 to USD 471.1 billion by 2032, at a robust CAGR of 33.2%. Key drivers include the drugs' efficacy in managing diabetes and obesity, driving high demand and clinical research advancements. The market is dominated by two major players, Novo Nordisk A/S and Eli Lilly and Company, creating significant entry barriers. Opportunities lie in expanding therapeutic applications beyond diabetes to include conditions like NASH and Alzheimer's disease. However, challenges such as patient non-adherence and the dominance of injectable formats hinder market growth. North America leads in market share, supported by accessibility and demand for GLP-1 analogues. Key players like Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca are pivotal in shaping market dynamics through extensive R&D and strategic expansions.

Download PDF Brochure: [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218746186&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Ozempic Leads the Charge in the GLP-1 Analogue Market

In 2023, Ozempic (semaglutide) dominated the GLP-1 Analogue market, buoyed by its significant revenue contribution and broad global application for diabetes treatment. Its market presence extends to obesity treatment under the brand Wegovy in Brazil, with a notable growth rate of approximately 70% from 2019 to 2023. Such robust performance underscores Ozempic's pivotal role in driving market expansion throughout the forecast period.

Single-Dose Formats Propel Growth in GLP-1 Analogue Adoption

The single-dose segment held the largest share of the GLP-1 Analogue market in 2023, a trend expected to persist. This dominance is attributed to the convenience and enhanced adherence facilitated by products like WEGOVY and TRULICITY, which offer comfortable weekly self-administration via autoinjectors. These advantages are set to bolster the segment's growth moving forward.

Subcutaneous Administration Commands Market Preference

In 2023, subcutaneous administration accounted for the largest market share in the GLP-1 Analogue segment, leveraging its ability to bypass gastrointestinal adverse effects and deliver rapid therapeutic effects. This preference is bolstered by the availability of diverse injector types, including pen injectors and autoinjectors, catering to varied patient needs.

Diabetes Indication Spearheads GLP-1 Analogue Market

The diabetes indication segment emerged as the largest in the GLP-1 Analogue market in 2023, driven by increasing demand for effective Type-2 Diabetes management. This growth is further supported by a robust research and development pipeline focusing on enhancing therapeutic outcomes compared to other antidiabetic drug classes.

Home Care Settings Drive GLP-1 Analogue Adoption

Home care settings dominated the GLP-1 Analogue market in 2023, facilitated by the convenience and patient adherence advantages offered by at-home drug administration. This trend is augmented by the expanding utilization of GLP-1 Analogue drugs in treating obesity outside traditional healthcare facilities.

North America Poised for Significant Growth in GLP-1 Analogue Market

North America, particularly the US, is expected to exhibit the highest growth rate in the GLP-1 Analogue market during the forecast period. This projection stems from increasing adoption of GLP-1 drugs for diabetes and obesity treatment, supported by well-established healthcare infrastructure and favorable reimbursement frameworks.

Request Sample Pages: [https://www.marketsandmarkets.com/requestsampleNew.asp?id=218746186&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Dominance of Novo Nordisk A/S in the GLP-1 Analogue Market

Novo Nordisk A/S (Denmark) stands as a pivotal force in the GLP-1 Analogue market, boasting a diverse product portfolio highlighted by flagship products like Ozempic and Wegovy. The company's extensive global distribution channels and robust R&D efforts underscore its leadership in insulin and GLP-1 manufacturing worldwide. Novo Nordisk's focus on developing oral formulations of existing GLP-1 drugs further enhances patient convenience and therapeutic efficacy.

Eli Lilly and Company's Strategic Expansion in GLP-1 Analogue Market

Eli Lilly and Company (US) plays a prominent role in advancing the GLP-1 Analogue market, with significant investments exceeding USD 9 billion in R&D during 2023 alone. The company's commercialized products, including Mounjaro, Trulicity, and Zepbound, contribute substantially to its revenue, with Trulicity and Mounjaro jointly accounting for approximately 36% of total earnings in 2023. Eli Lilly's ongoing focus on expanding its clinical pipeline reinforces its competitive position in the market.

Sanofi's Global Presence and Regulatory Advancements

Sanofi (France) maintains a strong foothold in the GLP-1 Analogue market through products like Soliqua, marketed in over 80 countries worldwide. The company's strategic approach includes securing regulatory approvals across diverse geographies, exemplified by recent approvals in China for Soliqua to enhance glycemic control in adults with type 2 diabetes. Sanofi's expansive geographic reach and rigorous regulatory strategies position it as a key player driving market growth and accessibility.

For more information, inquire now! [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=218746186&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glp1-analogues-market-worth-4711-billion-by-2032-marketsandmarkets]
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GLP-1 Analogues Market worth $471.1 billion by 2032 | MarketsandMarkets Trademark here

News-ID: 3685390 • Views:

More Releases from ABNewswire

Anti Drone Market Latest Trends 2024: Global Size, Share Analysis, Growth Opportunities, Report, Forecast 2032
Anti Drone Market Latest Trends 2024: Global Size, Share Analysis, Growth Opport …
The increasing privacy concerns due to unauthorized drone surveillance, the rising product demand to protect against the potential disruption of autonomous vehicles, and the growing use of drones in smuggling and contraband delivery are some of the factors propelling the anti drone market. Base Year: 2023 Forecast Years: 2024-2032 Historical Years: 2018-2023 Units: USD Million Market Size in 2023: USD 1,602.5 Million Market Forecast in 2032: USD 11,713.6 Million Market Compound Annual Growth Rate 2024-2032: 24% As indicated
Coronary Heart Disease Market Size, Epidemiology, Industry Trends and Forecast 2024-2034
Coronary Heart Disease Market Size, Epidemiology, Industry Trends and Forecast 2 …
Coronary heart disease is a medical condition that develops when the arteries carrying blood to the heart muscle become narrowed or blocked. Market Overview: Base Year: 2023 Historical Years: 2018-2023 Forecast Years: 2024-2034 Market Growth Rate: 5.17% (2024-2034) The [https://www.imarcgroup.com/coronary-heart-disease-market]. The coronary heart disease market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods,
Japan Software Market Size, Share, Growth, Demand, and Forecast 2024-2032
Japan Software Market Size, Share, Growth, Demand, and Forecast 2024-2032
The market is rapidly expanding, driven by digital transformation, cloud adoption, and increasing demand for innovative solutions across industries. Japan Software Market Overview: Base Year: 2023 Historical Years: 2018-2023 Forecast Years: 2024-2032 Market Growth Rate: 4.66% (2024-2032) According to the IMARC Group, Japan software market size is projected to exhibit a growth rate (CAGR) of 4.66% during 2024-2032 [https://www.imarcgroup.com/japan-software-market]. The market is rapidly expanding, driven by digital transformation, cloud adoption, and increasing demand for innovative solutions
Surgical Suction Instruments Industry worth $503 million in 2029, with a CAGR of 6.1%
Surgical Suction Instruments Industry worth $503 million in 2029, with a CAGR of …
Browse 250 market data Tables and 65 Figures spread through 285 Pages and in-depth TOC on "Surgical Suction Instruments Market by Type (Tubes, Tips, Restractors, Cannulae), Usability (Disposable, Reusable), Application (General Surgery, Neurosurgery, Orthopedic, Cardiovascular, Dental), End User - Global Forecast to 2029 The global surgical suction instruments market [https://www.marketsandmarkets.com/Market-Reports/surgical-suction-instruments-market-129636225.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] is projected to reach USD 503 million by 2029, growing at a CAGR of 6.1% from USD 375 million in 2024,

All 5 Releases


More Releases for Analogue

Cheese Analogue Market Share, Regional Analysis and Forecast To 2027 | Cheese An …
The global cheese analogue market is set to gain momentum from the increasing adoption of vegan diet. Hence, manufacturers are focusing on developing cheese alternatives for the processed food industry. This information is given by Fortune Business Insights™ in a new report, titled, "Cheese Analogue Market Size, Share & COVID-19 Impact Analysis, By Type (Non-dairy Cheese Analogues, Dairy Cheese Analogues, and Partial Dairy Cheese Analogues), Application (Bakery and Confectionery, Breakfast
Somatostatin Analogue Drug Market Trends, Growth, Analysis and Forecast - 2025
The global somatostatin analogue drug market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, and new product launches are some of the key factors contributing to the growth of the hormone therapy replacement therapy market across the globe. According to the American Cancer Society, there are around 5,000 new carcinoid tumors diagnosed in the US each year. According
Global Analogue Development Kits Market 2017 product price, profit, capacity, pr …
Market Research Report firstly introduced Global Analogue Development Kits Market 2017 Industry Trends, Sales, Supply, Demand, Analysis & Forecast. Global Analogue Development Kits Market Research Report 2017-2021 is in-depth study and comprehensive analysis on the Global Analogue Development Kits industry. This report is focuses on the major regional market conditions of Analogue Development Kits industry. It is aim is to provide deep and accurate analysis about industry size, company growth, recent
Meat Analogue 2017 Global Market Supply and Consumption Research Report 2022
Meat Analogue Market 2017 Report Details: Wiseguyreports.Com Adds “Meat Analogue Market –Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. In this report, we analyze the Meat Analogue industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the
Global Analogue Development Kits Market Research Report Forecast 2017-2021
Summary The Global Analogue Development Kits Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Analogue Development Kits industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Analogue Development Kits market study provides comprehensive data which enhances the
Analogue Development Kits Industry 2017 Global Market Research 2021
QY Market Research based on the Analogue Development Kits market across the globe, recently added to the repository , is titled ‘Global Analogue Development Kits Market 2017’. The research report analyzes the historical as well as present performance of the global Analogue Development Kits market, and makes predictions on the future status of Analogue Development Kits market on the basis of this analysis. Analogue Development Kits Industry 2017 Global